- Home
- CTSO vs NVNO Comparison
CTSO vs NVNO Comparison
Compare CTSO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- NVNO
- Stock Information
- Founded
- CTSO 1997
- NVNO 1987
- Country
- CTSO United States
- NVNO United States
- Employees
- CTSO N/A
- NVNO N/A
- Industry
- CTSO Medical/Dental Instruments
- NVNO Medical/Dental Instruments
- Sector
- CTSO Health Care
- NVNO Health Care
- Exchange
- CTSO Nasdaq
- NVNO Nasdaq
- Market Cap
- CTSO 52.6M
- NVNO 71.0M
- IPO Year
- CTSO N/A
- NVNO N/A
- Fundamental
- Price
- CTSO $1.07
- NVNO $3.95
- Analyst Decision
- CTSO Buy
- NVNO
- Analyst Count
- CTSO 2
- NVNO 0
- Target Price
- CTSO $5.50
- NVNO N/A
- AVG Volume (30 Days)
- CTSO 137.3K
- NVNO 112.5K
- Earning Date
- CTSO 08-12-2025
- NVNO 07-30-2025
- Dividend Yield
- CTSO N/A
- NVNO N/A
- EPS Growth
- CTSO N/A
- NVNO N/A
- EPS
- CTSO N/A
- NVNO N/A
- Revenue
- CTSO $35,332,238.00
- NVNO N/A
- Revenue This Year
- CTSO $18.34
- NVNO N/A
- Revenue Next Year
- CTSO $19.82
- NVNO N/A
- P/E Ratio
- CTSO N/A
- NVNO N/A
- Revenue Growth
- CTSO 15.37
- NVNO N/A
- 52 Week Low
- CTSO $0.71
- NVNO $2.03
- 52 Week High
- CTSO $1.61
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- CTSO 50.63
- NVNO 49.70
- Support Level
- CTSO $0.93
- NVNO $3.89
- Resistance Level
- CTSO $1.16
- NVNO $4.06
- Average True Range (ATR)
- CTSO 0.11
- NVNO 0.22
- MACD
- CTSO -0.02
- NVNO -0.05
- Stochastic Oscillator
- CTSO 38.18
- NVNO 14.06
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.